Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Metacrine Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2015
Status: Out of Business
BioCentury | Dec 15, 2023
Management Tracks
Amgen names Bradner CSO as Reese moves to CTO
Plus: Matthieu Coutet joins Sofinnova Partners, and updates from Vanqua Bio, Adela, Velia and more
BioCentury | Dec 23, 2022
Regulation
Dec. 23 Quick Takes: Lunsumio first bispecific for follicular lymphoma
Plus: FDA rebuffs Ipsen’s palovarotene; Amgen, LegoChem in ADC deal; spending bill to Biden; and updates from UCB, Intercept, Galapagos, Ryvu and more
BioCentury | Sep 7, 2022
Finance
Sept. 7 Quick Takes: Arch-backed Orbital launches with RNA platform
Plus Arpeggio raises $17M series A for transcriptional mechanisms, and updates from Equillium, BoomRay, Zealand and more
BioCentury | Jan 6, 2022
Management Tracks
COO Haviland to become new Blueprint CEO; Albers sliding to executive chair
Plus Galbraith succeeding Tehrani at Zymeworks and updates from Catalent, Bicycle, ADARx and more
BioCentury | Sep 1, 2021
Management Tracks
Zaks joins board at Teva
Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
BioCentury | Dec 12, 2020
Finance
RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies
With a $105 million series B, the radiopharmaceuticals platform newco can pursue multiple programs in parallel
BioCentury | Oct 15, 2020
Emerging Company Profile
RayzeBio pulling together radiotherapy platform with $45 million
RayzeBio combines the tumor-killing of actinium 225 with the target affinity and PK of macrocycles
BioCentury | Sep 19, 2020
Finance
Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B
Among a pair of companies that priced upsized IPOs ahead of Friday’s session, neurodegeneration play Athira gave back most of its early gains, while depression company Compass scored a
BioCentury | Sep 17, 2020
Product Development
Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies
Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT)
Items per page:
1 - 10 of 27